Slow start for Biogen Alzheimer's drug Leqembi

Taking stock of the drug industry, from the lab to the medicine chest

February 13, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Illustration: Alex Hogan/STAT; Photo: Eisai via AP STAT+ | Biogen Alzheimer's drug launch off to slow start Biogen's treatment for Alzheimer's disease, Leqembi, is being taken by about 2,000 U.S. patients seven months after its approval. By Jonathan Saltzman — Boston Globe STAT+ | Opinion: A California court is setting a dangerous precedent over drug development (or lack thereof) liability A California appeals court is letting a suit against Gilead for not developing an HIV drug proceed. That's a dangerous precedent. By Dan Troy STAT+ | Startup BioAge raises $170 million Series D for Zepbound combination therapy A California biotech developing a combination therapy with the blockbuster obesity drug Zepbound has raised a $170 million Series D round. By Allison DeAngelis Adobe STAT+ | KalVista pill reduces swelling symptoms caused by genetic disease, achieving goal of late-stage study The company plans to submit sebetralstat for FDA approval to relieve symptoms from hereditary angioedema, a disease that can be fatal. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser